Joung-Ho Rha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joung-Ho Rha has a total of 174 co-authors. Here are the top co-authors by number of shared publications:
- Cindy W. Yoon
Department of Neurology, Inha University School of Medicine, Incheon, Korea
7 shared publications - Ji Hoe Heo
Department of Neurology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea
7 shared publications - Keun-Sik Hong
Department of Neurology, Inje University Ilsan Paik Hospital, Goyang, Republic of Korea
6 shared publications Hee-Kwon Park
Department of Neurology, Inha University School of Medicine, 27 Inhang-ro, Jung-gu, Incheon 22332, Republic of Korea
5 shared publications- Byung Moon Kim
Department of Radiology, Yonsei University College of Medicine, Seoul, Korea
4 shared publications Hee-Joon Bae
Department of Neurology Seoul National University College of Medicine Seoul Korea
4 shared publications
Latest Publications
- Open Access
- 5 October 2022
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (42) , e305
Comparison of Factors Associated With Direct Versus Transferred-in Admission to Government-Designated Regional Centers Between Acute Ischemic Stroke and Myocardial Infarction in Korea
Kim DH, et al. J Korean Med Sci. 2022 Oct;37(42):e305. https://doi.org/10.3346/jkms.2022.37.e305
- 5 October 2022
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (42) , e305
Open AccessComparison of Factors Associated With Direct Versus Transferred-in Admission to Government-Designated Regional Centers Between Acute Ischemic Stroke and Myocardial Infarction in Korea
Kim DH, et al. J Korean Med Sci. 2022 Oct;37(42):e305. https://doi.org/10.3346/jkms.2022.37.e305
- Open Access
- 1 January 2021
- Published by XMLink in Journal of Clinical Neurology
- Vol. 17 (3) , 344-353
Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia: The Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia Study
Hong KS, et al. J Clin Neurol. 2021 Jul;17(3):344-353. https://doi.org/10.3988/jcn.2021.17.3.344
- 1 January 2021
- Published by XMLink in Journal of Clinical Neurology
- Vol. 17 (3) , 344-353
Open AccessFimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia: The Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia Study
Hong KS, et al. J Clin Neurol. 2021 Jul;17(3):344-353. https://doi.org/10.3988/jcn.2021.17.3.344
- Open Access
- 1 January 2021
- Published by Korean Neurological Association in Journal of Clinical Neurology
- Vol. 17 (1) , 145-146
Paraparesis in Unilateral Medial Medullary Infarction
Yoon CW, et al. J Clin Neurol. 2021 Jan;17(1):145-146. https://doi.org/10.3988/jcn.2021.17.1.145
- 1 January 2021
- Published by Korean Neurological Association in Journal of Clinical Neurology
- Vol. 17 (1) , 145-146
Open AccessParaparesis in Unilateral Medial Medullary Infarction
Yoon CW, et al. J Clin Neurol. 2021 Jan;17(1):145-146. https://doi.org/10.3988/jcn.2021.17.1.145
- 1 July 2020
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 29 (7) , 104859
A case report and experience of endovascular treatment for a patient with hemophilia who had a hyperacute ischemic stroke
- 1 July 2020
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 29 (7) , 104859
A case report and experience of endovascular treatment for a patient with hemophilia who had a hyperacute ischemic stroke
- 1 February 2020
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 29 (2) , 104510
Sleep Apnea and Early Neurological Deterioration in Acute Ischemic Stroke
- 1 February 2020
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 29 (2) , 104510
Sleep Apnea and Early Neurological Deterioration in Acute Ischemic Stroke
- Open Access
- 1 January 2018
- Published by The Korean Society of Radiology in Korean Journal of Radiology
- Vol. 19 (5) , 838-848
Consensus Statements by Korean Society of Interventional Neuroradiology and Korean Stroke Society: Hyperacute Endovascular Treatment Workflow to Reduce Door-to-Reperfusion Time
Kim DH, et al. Korean J Radiol. 2018 Sep-Oct;19(5):838-848. https://doi.org/10.3348/kjr.2018.19.5.838
- 1 January 2018
- Published by The Korean Society of Radiology in Korean Journal of Radiology
- Vol. 19 (5) , 838-848
Open AccessConsensus Statements by Korean Society of Interventional Neuroradiology and Korean Stroke Society: Hyperacute Endovascular Treatment Workflow to Reduce Door-to-Reperfusion Time
Kim DH, et al. Korean J Radiol. 2018 Sep-Oct;19(5):838-848. https://doi.org/10.3348/kjr.2018.19.5.838
- Open Access
- 1 January 2018
- Published by XMLink in Journal of Korean Medical Science
- Vol. 33 (19) , e143
Consensus Statements by Korean Society of Interventional Neuroradiology and Korean Stroke Society: Hyperacute Endovascular Treatment Workflow to Reduce Door-to-Reperfusion Time
Kim DH, et al. J Korean Med Sci. 2018 Apr;33(19):e143. https://doi.org/10.3346/jkms.2018.33.e143
- 1 January 2018
- Published by XMLink in Journal of Korean Medical Science
- Vol. 33 (19) , e143
Open AccessConsensus Statements by Korean Society of Interventional Neuroradiology and Korean Stroke Society: Hyperacute Endovascular Treatment Workflow to Reduce Door-to-Reperfusion Time
Kim DH, et al. J Korean Med Sci. 2018 Apr;33(19):e143. https://doi.org/10.3346/jkms.2018.33.e143
- Open Access
- 20 April 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (4) , e0176300
Is antiplatelet treatment effective at attenuating the progression of white matter hyperintensities?
We performed this study to assess the effect of an antiplatelet agent on the progression of white matter hyperintensities (WMH). From August 2003 to May 2005, we consecutively enrolled patients who underwent brain magnetic resonance imaging (MRI) for health check-up purposes and showed no significant findings other than WMH of any degree. Patients were divided into two groups based on whether or not they received antiplatelet therapy. All patients had a follow-up brain MRI after 5 years and WMH volume change was measured using imaging analysis software. To minimize selection bias potentially arising from antiplatelet treatment assignment, analyses were inverse probability weighted. Among the 93 patients who met the inclusion criteria, 54 patients (58.1%) were grouped as the antiplatelet group (AG), and the remaining 39 patients (41.9%) as the non-antiplatelet group (NAG). After inverse propensity weighting, all baseline characteristics were similar between the two groups, and antiplatelet treatment did not show any significant effect on the total WMH volume change (p = 0.957). Antiplatelet medication may not alter the progression of WMH.
- 20 April 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (4) , e0176300
Open AccessIs antiplatelet treatment effective at attenuating the progression of white matter hyperintensities?
We performed this study to assess the effect of an antiplatelet agent on the progression of white matter hyperintensities (WMH). From August 2003 to May 2005, we consecutively enrolled patients who underwent brain magnetic resonance imaging (MRI) for health check-up purposes and showed no significant findings other than WMH of any degree. Patients were divided into two groups based on whether or not they received antiplatelet therapy. All patients had a follow-up brain MRI after 5 years and WMH volume change was measured using imaging analysis software. To minimize selection bias potentially arising from antiplatelet treatment assignment, analyses were inverse probability weighted. Among the 93 patients who met the inclusion criteria, 54 patients (58.1%) were grouped as the antiplatelet group (AG), and the remaining 39 patients (41.9%) as the non-antiplatelet group (NAG). After inverse propensity weighting, all baseline characteristics were similar between the two groups, and antiplatelet treatment did not show any significant effect on the total WMH volume change (p = 0.957). Antiplatelet medication may not alter the progression of WMH.